What is the recommended pharmacologic and mechanical prophylaxis for deep vein thrombosis in pregnant patients with high‑risk factors such as prior DVT/PE, thrombophilia, obesity, multiple gestation, prolonged immobilization, or cesarean delivery?

DVT Prophylaxis for Pregnant Patients

All pregnant women undergoing cesarean delivery must receive sequential compression devices (SCDs) starting before surgery and continuing until fully ambulatory, and those with one major risk factor (prior VTE, high-risk thrombophilia, antiphospholipid syndrome) or two or more minor risk factors (obesity, advanced age ≥35 years, smoking, family history of VTE) should receive prophylactic low-molecular-weight heparin (enoxaparin 40 mg subcutaneously once daily) in addition to mechanical prophylaxis. 1

Universal Mechanical Prophylaxis

• Sequential compression devices are mandatory for all cesarean deliveries, applied pre-operatively and maintained until the patient achieves complete ambulation, regardless of other risk factors (GRADE 1C). 1
• Pneumatic compression devices are superior to elastic stockings and represent the minimum standard of care. 1

Risk Stratification Framework

Major Risk Factors (Any ONE warrants pharmacologic prophylaxis)

• Prior personal history of deep vein thrombosis or pulmonary embolism 2
• High-risk inherited thrombophilia: antithrombin deficiency, homozygous Factor V Leiden, homozygous prothrombin G20210A, or compound heterozygosity 2
• Antiphospholipid antibody syndrome 1
• Antepartum immobilization ≥1 week 1

Minor Risk Factors (TWO OR MORE warrant pharmacologic prophylaxis)

• Obesity (BMI ≥30 kg/m²) 2
• Advanced maternal age (≥35 years) 1
• Current smoking 1
• Family history of VTE in first-degree relative 2
• Emergency cesarean section 2
• Preeclampsia 2
• Multiple gestation 3
• Prolonged labor or postpartum hemorrhage >1 L 2

The American College of Chest Physicians establishes that when absolute VTE risk exceeds 3%, pharmacologic prophylaxis benefits outweigh harms—this threshold is met by one major factor or two or more minor factors. 1

Pharmacologic Prophylaxis Regimens

Standard Dosing (BMI <40 kg/m²)

• Enoxaparin 40 mg subcutaneously once daily is the preferred agent for VTE prophylaxis during pregnancy and postpartum (GRADE 1C). 1
• May be initiated as early as 4 hours after epidural catheter removal, but not earlier than 12 hours after neuraxial block placement. 1

Obesity-Adjusted Dosing (BMI ≥40 kg/m²)

• Intermediate-dose enoxaparin 40 mg subcutaneously every 12 hours is recommended for Class III obesity (GRADE 2C). 1
• This regimen requires ≥4 hours after catheter removal AND ≥24 hours after neuraxial block (different timing than standard dosing). 1
• Alternative weight-based regimen: 0.5 mg/kg subcutaneously every 12 hours more reliably achieves prophylactic anti-Xa levels in morbidly obese patients. 1

Renal Impairment Alternative

• Unfractionated heparin 5,000 units subcutaneously every 8–12 hours should replace enoxaparin when creatinine clearance <30 mL/min. 1
• UFH can be initiated as early as 1 hour after epidural catheter removal, providing a timing advantage. 1

Duration of Prophylaxis

Standard-Risk Patients

• Mechanical prophylaxis continues until full ambulation. 1
• Pharmacologic prophylaxis for at least 7–10 days or hospital discharge. 1

High-Risk Patients (Extended Prophylaxis)

• Women with prior VTE, any inherited thrombophilia (high- or low-risk), or antiphospholipid syndrome require both mechanical and pharmacologic prophylaxis extended to 6 weeks postpartum (GRADE 2C). 1
• Minimum total duration: 6 weeks after delivery when risk factors persist. 2, 1

Antepartum Prophylaxis for Specific Populations

Women with Prior VTE

• Antepartum prophylactic LMWH throughout pregnancy is recommended for women with unprovoked prior VTE or VTE associated with pregnancy/estrogen. 4, 5
• Women with prior provoked VTE (transient risk factor, no thrombophilia, no family history) may undergo antepartum surveillance without prophylaxis. 4, 5

Asymptomatic Thrombophilia WITHOUT Prior VTE

Heterozygous Factor V Leiden or Prothrombin Gene Mutation:

• Antepartum: Clinical surveillance only (no prophylaxis) regardless of family history (conditional recommendation, very low certainty). 2
• Postpartum: Clinical surveillance if no family history; prophylaxis for 6 weeks if positive family history of VTE (GRADE 2C). 2

Protein C or Protein S Deficiency:

• Antepartum: Clinical surveillance regardless of family history (conditional recommendation, very low certainty). 2
• Postpartum: Clinical surveillance if no family history; prophylaxis for 6 weeks if positive family history (GRADE 2C). 2

Compound Heterozygosity or Homozygous Mutations:

• Antepartum prophylaxis recommended regardless of family history (conditional recommendation, very low certainty). 2
• Postpartum prophylaxis for 6 weeks regardless of family history (conditional recommendation, very low certainty). 2

Critical Timing Considerations with Neuraxial Anesthesia

• Standard enoxaparin (40 mg once daily): ≥4 hours after catheter removal AND ≥12 hours after neuraxial block. 1
• Intermediate enoxaparin (40 mg every 12 hours): ≥4 hours after catheter removal AND ≥24 hours after neuraxial block. 1
• Unfractionated heparin: ≥1 hour after catheter removal. 1

Common Pitfalls to Avoid

• Do not use standard-dose enoxaparin (40 mg once daily) in Class III obesity (BMI ≥40)—this results in subtherapeutic anti-Xa levels in the majority of patients. 1
• Do not use direct oral anticoagulants (DOACs) or warfarin for prophylaxis during pregnancy or immediate postpartum—insufficient safety data and teratogenic risk. 1, 6
• Do not delay mechanical prophylaxis—SCDs must be applied pre-operatively, not after skin closure. 1
• Do not provide pharmacologic prophylaxis to low-risk cesarean patients—the number needed to harm (wound complications, bleeding) may be lower than the number needed to treat for VTE prevention. 2, 1
• Do not initiate intermediate-dose enoxaparin before 24 hours post-neuraxial block—this increases spinal hematoma risk. 1

Institutional Implementation

• Each institution should develop a standardized VTE prophylaxis bundle incorporating pre-operative SCD application, systematic risk-factor screening using a validated tool (ACCP, RCOG, or modified Caprini), and weight-based dosing protocols (Best Practice). 1
• Adoption of standardized order sets reduces practice variation and improves compliance with evidence-based prophylaxis. 1

Evidence Quality and Guideline Consensus

The certainty of benefit from prophylaxis in women with clinical risk factors alone (without prior VTE or thrombophilia) is low to very low due to lack of adequately powered randomized trials. 2 However, the American Society of Hematology 2018 guidelines acknowledge that most other international societies (ACOG, RCOG, SOGC, ACCP) recommend a more liberal approach to prophylaxis based on clinical risk stratification, which is reflected in the recommendations above. 2, 1